Fluticasone furoate 0.2 mg/ACTUAT / umeclidinium 0.0625 mg/ACTUAT / vilanterol 0.025 mg/ACTUAT [Trelegy]
RxNorm 2395770
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2395770 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: fluticasone furoate 0.2 mg/ACTUAT / umeclidinium 0.0625 mg/ACTUAT / vilanterol 0.025 mg/ACTUAT [Trelegy].
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
Semantic Branded Drug Component (SBDC):
Fluticasone furoate 0.2 mg/ACTUAT / umeclidinium 0.0625 mg/ACTUAT / vilanterol 0.025 mg/ACTUAT [Trelegy]
(Atom ID: 12435294)
Patient Education
Fluticasone, Umeclidinium, and Vilanterol Oral Inhalation
The combination of fluticasone, umeclidinium, and vilanterol is used to control wheezing, shortness of breath, coughing, and chest tightness caused by chronic obstructive pulmonary (COPD; a group of diseases that affect the lungs and airways, that includes chronic bronchitis and emphysema). It is also used in adults to control wheezing, shortness of breath, coughing, and chest tightness caused by asthma. Fluticasone is in a class of medications called steroids. Umeclidinium is in a class of medication called anticholinergics. Vilanterol is in a class of medications called long-acting beta-agonists (LABAs). The combination of fluticasone, umeclidinium, and vilanterol works by relaxing and opening air passages in the lungs, making it easier to breathe.
[Learn More]
* Please review the disclaimer below.